The Weekly Recap 2/20/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, receive regulatory approvals, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

AMT Medical

Appointed Geert van Gansewinkel as CEO to lead the company into its next phase of development of the ELANA^Ⓡ Heart Bypass System as it approaches key clinical milestones expected to define its regulatory pathway and commercial trajectory. Founder and former CEO Rutger Tulleken will transition to Founder and Strategic Advisor, where he will continue contributing to AMT’s innovation roadmap, IP strategy, and strategic partnerships.

Arbutus Medical

Closed an oversubscribed C$9.3M growth financing led by Crédit Mutuel Equity, with participation from the CU Healthcare Innovation Fund and existing investors, to accelerate expansion of its surgical workflow solutions outside the operating room. The funding will support commercial team growth, clinical education programs, manufacturing scale-up, and the launch of new products.

Augmedics

Shared that VB Spine announced it has entered into a definitive agreement to acquire exclusive rights to the xvision Spine System^Ⓡ from Augmedics. The agreement, expected to close in the coming weeks, will strengthen Augmedics’ competitive advantage as an augmented reality innovation engine as the company turns its focus to expanding into adjacent surgical indications.

Berlin Heals

Announced the successful close of a new financing round, raising over $10M to advance its cardiac microcurrent technology and expand its clinical research program. The funding will support less invasive implantation techniques, expanded indications, larger double-blinded trials, and preparation for an FDA IDE submission as the company moves toward global commercialization.

Ferys Capital

Was officially launched by LSI Alumni David Cubbin, alongside his co-founder and partner ​​Sebastian Gührs. The hands-on investment house is focused on actively partnering with founders to build and scale resilient, commercially successful healthtech companies, working with portfolio companies including Neteera, Virasoft, and Cerryx.

Ibex Medical Analytics

Appointed Yair Heller as CEO, with co-founder Joseph Mossel transitioning to lead the company’s biopharma division and U.S. clinical growth initiatives. The leadership transition comes alongside continued global adoption and commercial momentum, including major clinical deployments, expanded customer growth, and accelerating expansion into life sciences and drug development.

InkSpace Imaging

Shared that Philips announced the availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems. The collaboration combines Philips’ MRI leadership with InkSpace Imaging’s pediatric-first, flexible coil design to enhance comfort for children while supporting high-resolution imaging and workflow efficiency for clinicians.

InVera Medical

Received CE Mark approval for its InVera Infusion Device, a new minimally invasive, non-thermal device designed to help physicians deliver treatment more effectively to diseased leg veins, including varicose veins. The milestone allows the device to be marketed and used across the European Union, an important step forward in expanding non-thermal options for physicians in the management of chronic venous disease.

Medical 21

Filed a Form S-1 with the U.S. SEC to initiate the process of an initial public offering, seeking to offer nearly 2.3 million shares of common stock, expected to be priced between $10 and $12 per share. The company expects to use the anticipated net proceeds to complete a first-in-human clinical trial, begin an expanded feasibility study, continue animal studies, and support regulatory and development activities.

Neuromod

Announced new data supporting the use of its Lenire tinnitus treatment device in U.S. patients. The paper, written by Dr. Craig Kasper, found that 81.8% of 140 patients treated with Lenire reported relief from tinnitus and had a mean reduction of 23.8 points on the Tinnitus Handicap Inventory (THI) scale.

OncoRes Medical

Completed an A$27M private funding round to support the clinical development and regulatory advancement of its quantitative micro-elastography imaging system, Elora™. As part of its initiative toward regulatory approval and commercialization in the U.S. market, the company appointed Renee Ryan as a new board member.

Retia Medical

Received FDA 510(k) clearance for Argos Infinity™, its cardiovascular intelligence software platform designed for high-risk surgical and critical care environments. The platform analyzes real-time physiologic data from existing monitoring and tele-ICU systems and transforms those signals into actionable hemodynamic insight in operating rooms and intensive care units, without requiring replacement of current monitoring infrastructure.

Sinaptica Therapeutics

Announced that it’s in the process of closing its $9M oversubscribed funding round. Sinaptica Therapeutics is a Cambridge, MA-based, clinical-stage company that has developed a personalized closed-loop neuromodulation therapy for Alzheimer’s Disease.

Synchrony Medical

Closed an oversubscribed $5M funding round led by Edge Medical Ventures to accelerate U.S. commercial expansion of its FDA-cleared LibAirty™ Airway Clearance System and support ongoing clinical research and product development. Alongside the financing, the company announced the appointment of Kevin Kotler and Elad Duschak to its Board of Directors, strengthening its strategic oversight as it enters its next phase of growth.

Vektor Medical

Announced the publication of a peer-reviewed study in EP Europace evaluating vMap-guided activation mapping and ablation in patients with hemodynamically unstable ventricular tachycardia. The study demonstrated 80% one-year arrhythmia-free survival in the vMap group compared to 43% with conventional ablation strategies, without increases in procedure time, fluoroscopy exposure, or complications.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.